Hydroxyprogesterone caproate injection (makena) one year later: To compound or not to compound-that is the question

P and T

Volumn 37, Issue 7, 2012, Pages 405-411

  Patel, Yesha ^a   Rumore, Martha M ^b,c,d  

^a ST JOHN'S UNIVERSITY   (United States)

^b Clinical and Educational Services   (United States)

^c Children's Medical Center   (United States)

^d TOURO COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; PLACEBO; PROGESTERONE;

ARTICLE; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG SAFETY; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HUMAN; IMMINENT ABORTION; LEGAL LIABILITY; PREGNANCY; PREMATURE LABOR; PROPHYLAXIS; RECURRENCE RISK; RECURRENT ABORTION; UTERUS CANCER;

EID: 84865635252     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Society for Maternal Fetal Medicine Publications Committee. ACOG Committee Opinion No. 419 October 2008 (replaces No. 291, November 2003): Use of progesterone to reduce preterm birth. Obstet Gynecol 2008;112(4):963-965.
2. Preventing Preterm Birth: The Role of 17α-Hydroxyprogesterone Caproate. Albany, N.Y.: American College of Obstetricians and Gynecologists, District II; January 2009. Available at: http://mail. ny.acog.org/website/17PResourceGuide.pdf. Accessed November 9, 2011.
3. Da Fonseca E, Celik E, Parra M, et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007;357:462-469.
4. Meis PJ, Klebonoff M, Thorn E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-2385.
5. Lexicomp Online. Hydroxyprogesterone caproate. Available at: www.lexi.com; http://online.lexi.com. Accessed February 9, 2011.
6. Makena (hydroxyprogesterone caproate injection), prescribing information. St. Louis, Mo.: Ther-Rx Corp.; February 2011. Avail- able at: www.makena.com/media/PDFs/full-pi.pdf. Accessed February 9, 2011.
7. ACOG Committee Opinion. Use of progesterone to reduce preterm birth. Obstet Gynecol 2003;102(5 Part 1):1115-1116.
8. Northen AT, Normal GS, Anderson K, et al. Follow-up of children exposed in utero to 17α-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007;110:865-872.
9. Joy S, Rhea DJ, Istwan NB, et al. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention. Am J Perinatol 2010; 27(4):343-348.
10. FDA. FDA approves drug to reduce risk of preterm birth in at-risk pregnant women, February 4, 2011. Available at: www.fda. gov/ NewsEvents/Newsroom/PressAnnouncements/ucm 242234. htm. Accessed November 9, 2011.
11. Armstrong J. Unintended consequences: The cost of preventing preterm births after FDA approval of a branded version of 17OHP. N Engl J Med 2011;364:1689-1691.
12. FDA statement on Makena, March 30, 2011. Available at www.fda. gov/newsEvents/Newsroom/PressAnnouncements/ ucm249025. htm. Accessed November 9, 2011.
13. Food, Drug, and Cosmetic Act of 1938, Pub. L. No. 75-717, 52 Stat. 1040 §201(j).
14. American College of Obstetricians and Gynecologists. Makena price reduction is inadequate, April 1, 2011. Available at: www. acog.org/About_ACOG/News_Room/News_Releases/2011/ Makena_Price_Reduction_Is_Inadequate. Accessed February 28, 2012.
15. ®). June 15, 2012. Available at: www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm308546.htm. Accessed June 15, 2012.
16. Center for Medicaid, CHIP, and Survey & Certification (CMCS). CMCS Informational Bulletin. Makena, March 30, 2011. Available at: https://www.cms.gov/ CMCSBulletins/downloads/Makena-CMCS-Info-Bulletin-03-30-2011.pdf. Accessed November 28, 2011.
17. Maas A. FDA OKs compounding of 17P: Plans say they will still cover it. Specialty Pharm News 2011;8(4):6-7.
18. Behrman RE, Butler AS, eds. Preterm Birth: Causes, Consequences, and Prevention. Washington, D.C.: National Academy Press; 2006.
19. Farine D, Dodd J, Basso M, et al. The use of progesterone for prevention of preterm birth. J Obstet Gynaecol Can 2008;30(1): 67-71.
20. Cunningham FG, Leveno KJ, Bloom SL, et al. Preterm birth. In: Cunningham FG, Williams JW, Leveno KJ, eds. Williams Obstetrics, 23rd ed, chapter 36. New York: McGraw-Hill; 2011:804-831.
21. FDA Statement on Makena, March 30, 2011. Available at: www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm249025. htm. Accessed June 15, 2012.
22. Western States, 535 U.S. at 360-66.
23. FDA. Inspections, Compliance, Enforcement, and Criminal Investigations. Section 460.200: Pharmacy Compounding. May 29, 2002. Available at www.fda.gov/ICECI/Compliance Manuals/ CompliancePolicyGuidanceManual/ucm116791.htm. Accessed November 9, 2011.
24. Food and Drug Modernization and Accountability Act of 1997. Act. 21 U.S.C. § 353a(b)(1)(D).
25. Florida Administrative Code Ann. 64B16-27.700(1).
26. Reuters. Law offices of Howard G. Smith announces class action lawsuit against KV Pharmaceutical Company, November 2, 2011. Available at: www.reuters.com/article/2011/11/03/idUS24830+03- Nov-2011+BW20111103. Accessed November 9, 2011.
27. Progesterone Vaginal Gel 8% (Watson Pharmaceuticals/Columbia Laboratories). Available at: http://ir.watson.com/phoenix. zhtml?c=65778&p=irol-newsArticle&ID=1665690&highlight. Accessed June 15, 2012.
28. Romero R, Nicolaides K, Conde-Agudelo A, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery andneonatal morbidity: A systematic review and meta-analysis of individual patient data. Am J Obstet Gynecol 2012;206:124.e1- 124.e19.
29. Thornton J. The drugs we deserve. Br J Obstet Gynecol 2003;110: 969-970.